Q-omics provides the Sirolimus response profile across cancer cell-line models in the CCLE and GDSC pharmacogenomic screens. Sirolimus, a mTOR inhibitor inhibitor, shows drug-response associations across 1 molecular data types, most extensively with RNA-expression features, with the highest sampling consensus in NCI60_ALL. NCI60_ALL shows the largest number of associated molecular features.

Each association is evaluated using two consensus scores. Sampling consensus shows how consistently a biomarker separates sensitive and resistant cell lines across repeated analysis settings. Lineage consensus shows how widely the same biomarker–response association appears across cancer lineages, distinguishing broadly shared signals from lineage-specific ones.

Cross-omics associations

This table summarizes molecular features associated with Sirolimus sensitivity in cancer cell lines. Drug sensitivity data from CCLE and GDSC were compared with RNA expression, mutation, CRISPR, and shRNA dependency data. The Strength column shows the number of significant associated features for each molecular layer, and the Lineage column indicates the cancer lineage where the largest associated feature set is observed. The response to Sirolimus is most broadly linked to RNA-expression features, especially in NCI60_ALL.

Associated data type	Strength (# associated data)	Lineage of highest associated data
▼Inducing drug
RNA	697	NCI60_ALL (697)	view →